Key statistics
As of last trade, Fate Therapeutics Inc (F6T:FRA) traded at 2.92, 85.08% above the 52 week low of 1.58 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.92 |
---|---|
High | 2.92 |
Low | 2.92 |
Bid | 2.73 |
Offer | 2.76 |
Previous close | 2.81 |
Average volume | 624.38 |
---|---|
Shares outstanding | 113.88m |
Free float | 111.40m |
P/E (TTM) | -- |
Market cap | 366.69m USD |
EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:22 BST.
More ▼
Announcements
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
- Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
- Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
More ▼